Publication: Estudio de biomarcadores a partir de ADN tumoral circulante en pacientes con cáncer de pulmón no microcítico avanzado
Loading...
Files
Official URL
Full text at PDC
Publication Date
2019-08-26
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
El estudio de biomarcadores en pacientes con cáncer de pulmón no microcítico avanzado ha adquirido un importante papel en el abordaje terapéutico de esta enfermedad, gracias al desarrollo de fármacos dirigidos basados en el perfil mutacional del tumor. Estos fármacos actúan inhibiendo el dominio tirosin-kinasa de receptores transmembrana aberrantes, por lo que reciben el nombre de inhibidores de tirosin-kinasa. Los más importantes son aquellos que actúan frente a las alteraciones localizadas en el gen del Receptor del Factor de Crecimiento Epidérmico o Epidermal Growth Factor Receptor (EGFR), y que se conocen como EGFR-TKIs...
Biomarker testing in advanced non-small cell lung cancer patients has assumed a major role due to the development of therapeutic agents specifically targeting tumoral molecular alterations. These drugs act by blocking the tyrosine-kinase domain against aberrant receptors and are known as Tyrosine-Kinase Inhibitors (TKIs), the most important being Epidermal Growth Factor Receptor-TKIs (EGFR-TKIs).However, biomarker testing may be hindered by the basic limitations of conventional biopsy, such as difficult access to tumor tissue, poor sample quality or negative impact on patient quality of life. Some of these limitations may be sidestepped by using circulating tumor DNA (ctDNA), which provides data on the mutational status of the tumor in a non-invasive way...
Biomarker testing in advanced non-small cell lung cancer patients has assumed a major role due to the development of therapeutic agents specifically targeting tumoral molecular alterations. These drugs act by blocking the tyrosine-kinase domain against aberrant receptors and are known as Tyrosine-Kinase Inhibitors (TKIs), the most important being Epidermal Growth Factor Receptor-TKIs (EGFR-TKIs).However, biomarker testing may be hindered by the basic limitations of conventional biopsy, such as difficult access to tumor tissue, poor sample quality or negative impact on patient quality of life. Some of these limitations may be sidestepped by using circulating tumor DNA (ctDNA), which provides data on the mutational status of the tumor in a non-invasive way...
Description
Tesis de la Universidad Complutense de Madrid, Facultad de Farmacia, Departamento de Bioquímica y Biología Molecular, leída el 10/05/2019